Evidence map›Paper›PMID 34130128›Full record

ArticleJournal of substance abuse treatment2022

Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV.

Amy J Kennedy, Kathleen A McGinnis, Jessica S Merlin, E Jennifer Edelman, Adam J Gordon, P Todd Korthuis, Melissa Skanderson, Emily C Williams, Jessica Wyse, Benjamin Oldfield and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of substance abuse treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Amy J KennedyDivision of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Kathleen A McGinnisVA Connecticut Healthcare System, West Haven, CT, USA.
Jessica S MerlinDivision of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
E Jennifer EdelmanDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA.
Adam J GordonProgram for Addiction Research, Clinical Care, Knowledge and Advocacy, Division of Epidemiology, Department of Internal Medicine, University of Utah; Informatics, Decision-Enhancement, and Analytic Sciences Center, VA Salt Lake City Health Care System, Salt Lake City, UT, USA.
P Todd KorthuisDivision of General Internal Medicine, Section of Addiction Medicine, Oregon Health and Sciences University, Portland, OR, USA.
Melissa SkandersonVA Connecticut Healthcare System, West Haven, CT, USA.
Emily C WilliamsDepartment of Health Services, University of Washington, VA Puget Sound Healthcare System, Seattle, WA, USA; Seattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Health Services Research & Development VA Puget Sound Healthcare System, Seattle, WA, USA.
Jessica WyseVA Portland Healthcare System, Portland, OR, USA; School of Public Health, Oregon Health and Sciences University, Portland, OR, USA.
Benjamin OldfieldDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Kendall BryantNational Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Amy JusticeVA Connecticut Healthcare System, West Haven, CT, USA; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
David A FiellinDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA.
Kevin L KraemerDivision of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA; VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. Electronic address: kraemerkl@upmc.edu.
VA Connecticut Healthcare System · USYale University · USUniversity of Pittsburgh · USHealth Services Research & Development · USNational Institute on Alcohol Abuse and Alcoholism · USOregon Health & Science University · USVA Pittsburgh Healthcare System · USVA Portland Health Care System · USVA Salt Lake City Healthcare System · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Alcohol Associated Outcomes Among HIV+/- Aging VeteransU10AA013566 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2006 to 2010
$12.7M
Alcohol and Multisubstance Use in the Veterans Aging Cohort StudyU01AA020790 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$7.7M
Sex Disparities in Overall Response to ART Among HIV Infected IndividualsU24AA020794 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$5.5M
Comparative Effectiveness of Alcohol and Drug Treatment in HIV-Infected VeteransR01AA022886 · NIAAA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KRAEMER, KEVIN L · 2014 to 2018
$2.4M
The University of Pittsburgh Postdoctoral Program in Health Services ResearchT32HS017587 · AHRQ · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KRAEMER, KEVIN L · 2008 to 2013
$1.2M
Expanding access to opioid use disorder treatment with buprenorphine in rural primary care settingsIK2HX003007 · VA · PORTLAND VA MEDICAL CENTER · PI WYSE, JESSICA JASMINE · 2020 to 2024
–
AHRQ HHS T32 HS017587HSRD VA IK2 HX003007NCATS NIH HHS UL1 TR001863NIAAA NIH HHS R01 AA022886NIAAA NIH HHS U01 AA020790NIAAA NIH HHS U10 AA013566NIAAA NIH HHS U24 AA020794
6 · The paper itself

Abstract

backgroundPersons with HIV (PWH) and opioid use disorder (OUD) can have poor health outcomes. We assessed whether intensity of behavioral treatment for OUD (BOUD) with and without medication for OUD (MOUD) is associated with improved HIV clinical outcomes.

methodsWe used Veterans Aging Cohort Study (VACS) data from 2008 to 2017 to identify PWH and OUD with ≥1 BOUD episode. We assessed BOUD intensity and ≥6 months of MOUD (methadone or buprenorphine) receipt during the 12 months after BOUD initiation. Linear regression models assessed the association of BOUD intensity and MOUD receipt with pre-post changes in log viral load (VL), CD4 cell count, VACS Index 2.0, antiretroviral treatment (ART) initiation, and ART adherence.

resultsAmong 2419 PWH who initiated BOUD, we identified five distinct BOUD intensity trajectories: single visit (39% of sample); low-intensity, not sustained (37%); high-intensity, not sustained (9%); low-intensity, sustained (11%); and high-intensity, sustained (5%). MOUD receipt was low (17%). Among 709 PWH not on ART at the start of BOUD, ART initiation increased with increased BOUD intensity (p < 0.01). Among 1401 PWH on ART at the start of BOUD, ART adherence improved more in higher-intensity BOUD groups (p < 0.01). VL, CD4 count and VACS Index 2.0 did not differ by BOUD or ≥6 months of MOUD treatment.

conclusionAmong PWH and OUD who initiated BOUD, higher intensity BOUD was associated with improved ART initiation and adherence, but neither BOUD alone nor BOUD plus ≥6 months MOUD was associated with improvements in VL, CD4 count or VACS Index 2.0.

Indexed as

BuprenorphineHIV InfectionsOpioid-Related DisordersCohort StudiesHumansMethadoneBuprenorphineMethadoneBehavioral treatmentHIVMedication treatmentOpioid use disorderVeterans

Identifiers

PMID34130128
PMCPMC8628025
OpenAlexW3170992498

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.